{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:33:33Z","timestamp":1794083613167,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Edumed - Educa\u00e7\u00e3o em Saude","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The inadequate storage of biopharmaceuticals may result in an ineffective therapeutic response since poor conservation can lead to the emergence of protein aggregates and cause immunogenicity in patients, which can increase the risk of adverse events by inducing the production of anti-drug antibodies. This can also lead to significant economic losses for public health, given the high cost of these medicines. The aim of this study was to verify whether the home storage of biopharmaceuticals dispensed by the Unified Public System was in accordance with the manufacturers\u2019 specified standards and whether external variables interfered with the correct home storage.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a prospective observational study. Patients with a confirmed diagnosis of rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis who were using a biologic exclusively dispensed by Unified Public System were included. Storage temperature was measured by digital thermometer inserted into the refrigerator of the participant\u2019s home. Fisher\u2019s exact test was performed to cross-reference the temperature data and the qualitative variables obtained using an epidemiologic questionnaire. Mean, minimum, maximum values and standard deviation were described in the quantitative data. Mann-Whitney non-parametric test was performed to the association between temperature excursion and the number of people in the house.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 81 participants were included and 67 (82.71%) did not maintain home storage correctly. The maximum temperature observed among all patients was 15.5\u2009\u00b0C, the minimum was \u2212\u20094.4\u2009\u00b0C and the average was 5.6\u2009\u00b0C (standard deviation 2.8); 10 (12.3%) had at least one negative temperature measured. The average time for participants who had an inadequate temperature record was 8\u2009h and 31\u2009min. Nine participants (90%) who stored the medication into the shelf\/drawer below the freezer had a temperature excursion (<jats:italic>p<\/jats:italic>\u2009=\u20090.011). Most of the participants (88.5%) who stored their biopharmaceutical near the back side, close to the wall of the refrigerator had a negative temperature record (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Most of the study participants (82.71%) did not maintain adequate home storage conditions for their biopharmaceutical. Intrinsic factors of household refrigerators may be involved in temperature deviations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s42358-020-00131-x","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T09:02:48Z","timestamp":1590570168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Home storage of biological medications administered to patients with rheumatic diseases"],"prefix":"10.1186","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-3686","authenticated-orcid":false,"given":"Glaucia","family":"Santin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Moreira Magnabosco","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Augusto","family":"Villarreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leane Dhara Dalle","family":"Laste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"de Freitas Montin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Eduardo Ribeiro","family":"Betiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valderilio Feij\u00f3","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"4","key":"131_CR1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/rheumatology\/kev394","volume":"55","author":"ND Vlieland","year":"2016","unstructured":"Vlieland ND, et al. The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology. 2016;55(4):704\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kev394.","journal-title":"Rheumatology"},{"issue":"1","key":"131_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-12-43","volume":"12","author":"A M\u00f3csai","year":"2014","unstructured":"M\u00f3csai A, Kov\u00e1cs L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12(1):1\u20139. https:\/\/doi.org\/10.1186\/1741-7015-12-43.","journal-title":"BMC Med"},{"issue":"2","key":"131_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijpharm.2010.02.025","volume":"390","author":"W Wang","year":"2010","unstructured":"Wang W, Nema S, Teagarden D. Protein aggregation-pathways and influencing factors. Int J Pharm. 2010;390(2):89\u201399. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.02.025 Epub 2010 Feb 24.","journal-title":"Int J Pharm"},{"issue":"3","key":"131_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7399\/FH.2014.38.3.1164","volume":"38","author":"I Ricote-Lobera","year":"2014","unstructured":"Ricote-Lobera I, et al. Estabilidad de los medicamentos termolabiles ante una interrupcion accidental de la cadena de frio. Farm Hosp. 2014;38(3):169\u201392. ISSN 2171-8695. https:\/\/doi.org\/10.7399\/FH.2014.38.3.1164.","journal-title":"Farm Hosp"},{"issue":"2","key":"131_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","volume":"105","author":"EM Moussa","year":"2016","unstructured":"Moussa EM, et al. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105(2):417\u201330. https:\/\/doi.org\/10.1016\/j.xphs.2015.11.002.","journal-title":"J Pharm Sci"},{"issue":"9","key":"131_CR6","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1002\/jps.21566","volume":"98","author":"HC Mahler","year":"2009","unstructured":"Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98(9):2909\u201334. https:\/\/doi.org\/10.1002\/jps.21566.","journal-title":"J Pharm Sci"},{"issue":"3","key":"131_CR7","doi-asserted-by":"publisher","first-page":"E501","DOI":"10.1208\/aapsj080359","volume":"8","author":"AS Rosenberg","year":"2006","unstructured":"Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501\u20137.","journal-title":"AAPS J"},{"key":"131_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis fator (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165\u201378. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202545.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"131_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.autrev.2015.02.007","volume":"14","author":"M Deehan","year":"2015","unstructured":"Deehan M, Garces S, Kramer D, Baker MP, Rat D, Roettger Y, et al. Managing unwanted immunogenicity of biologicals. Autoimmun Rev. 2015;14(7):569\u201374. https:\/\/doi.org\/10.1016\/j.autrev.2015.02.007 Epub 2015 Mar 2.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"131_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA van Schouwenburg","year":"2013","unstructured":"van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164\u201372. https:\/\/doi.org\/10.1038\/nrrheum.2013.4.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"131_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/jid.2014.295","volume":"135","author":"D Jullien","year":"2015","unstructured":"Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol. 2015;135(1):31\u20138. https:\/\/doi.org\/10.1038\/jid.2014.295.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"131_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/BOR.0b013e3283521c4e","volume":"24","author":"C Krieckaert","year":"2012","unstructured":"Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24(3):306\u201311. https:\/\/doi.org\/10.1097\/BOR.0b013e3283521c4e.","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"131_CR13","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/ annrheumdis-2012-202220","volume":"72","author":"S Garce\u02c6s","year":"2013","unstructured":"Garce\u02c6s S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947\u201355. https:\/\/doi.org\/10.1136\/%20annrheumdis-2012-202220.","journal-title":"Ann Rheum Dis"},{"key":"131_CR14","volume-title":"Espondilite anquilosante","author":"M Da Sa\u00fade","year":"2017","unstructured":"Da Sa\u00fade M. Espondilite anquilosante. Brasil: Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas; 2017. http:\/\/portalarquivossaudegovbr\/images\/pdf\/2017\/agosto\/03\/PCDT- Accessed 18 July 2019."},{"issue":"10","key":"131_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.12968\/bjcn.2015.20.10.481","volume":"20","author":"E Purssell","year":"2015","unstructured":"Purssell E. Reviewing the importance of the cold chain in the distribution of vaccines. Br J Community Nurs. 2015;20(10):481\u20136. https:\/\/doi.org\/10.12968\/bjcn.2015.20.10.481.","journal-title":"Br J Community Nurs"},{"key":"131_CR16","unstructured":"NOVUS, Produtos eletr\u00f4nicos. http:\/\/www.novus.com.br\/produtos\/732906. Accessed 18 July 2019."},{"issue":"2","key":"131_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cali.2009.09.001","volume":"25","author":"MJ Cu\u00e9llar","year":"2010","unstructured":"Cu\u00e9llar MJ, et al. Calidad en la conservaci\u00f3n de los medicamentos termol\u00e1biles en el \u00e1mbito domiciliario. Revista de Calidad Asistencial. 2010;25(2):64\u20139. https:\/\/doi.org\/10.1016\/j.cali.2009.09.001.","journal-title":"Revista de Calidad Asistencial"},{"issue":"2","key":"131_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/jgh.13920","volume":"33","author":"MJ De Jong","year":"2018","unstructured":"De Jong MJ, et al. Exploring conditions for redistribution of anti-tumor necrosis factors to reduce spillage: a study on the quality of anti-tumor necrosis factor home storage. J Gastroenterol Hepatol. 2018;33(2):426\u201330. https:\/\/doi.org\/10.1111\/jgh.13920.","journal-title":"J Gastroenterol Hepatol"},{"key":"131_CR19","volume-title":"Cuidados no armazenamento de medicamentos sob refrigera\u00e7\u00e3o","author":"J Rapkiewicz","year":"2014","unstructured":"Rapkiewicz J, Grobe R. Cuidados no armazenamento de medicamentos sob refrigera\u00e7\u00e3o; 2014."},{"issue":"1","key":"131_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jfoodeng.2007.03.032","volume":"87","author":"SJ James","year":"2008","unstructured":"James SJ, Evans J, James C. A review of the performance of domestic refrigerators. J Food Eng. 2008;87(1):2\u201310.","journal-title":"J Food Eng"},{"issue":"1","key":"131_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12603-013-0359-2","volume":"18","author":"CGM Sino","year":"2014","unstructured":"Sino CGM, et al. Medication management capacity in relation to cognition and self-management skills in older people on polypharmacy. J Nutr Health Aging. 2014;18(1):44\u20139. https:\/\/doi.org\/10.1007\/s12603-013-0359-2.","journal-title":"J Nutr Health Aging"},{"key":"131_CR22","volume-title":"Enquete p\u00fablica de medicamentos biol\u00f3gicos","author":"M da Sa\u00fade","year":"2018","unstructured":"Minist\u00e9rio da Sa\u00fade (2018). Enquete p\u00fablica de medicamentos biol\u00f3gicos. http:\/\/portalarquivos2.saude.gov.br\/images\/pdf\/2018\/outubro\/19\/Resultado-Enquete-Problemas-Versao-Publica.pdf. ."},{"key":"131_CR23","first-page":"16","volume-title":"Manual de Processos de Trabalho do Centro de Dispensa\u00e7\u00e3o de Medica\u00e7\u00e3o de Alto Custo (CEDMAC)","author":"MB B\u00e9rtolo","year":"2012","unstructured":"B\u00e9rtolo MB, et al. Manual de Processos de Trabalho do Centro de Dispensa\u00e7\u00e3o de Medica\u00e7\u00e3o de Alto Custo (CEDMAC). Campinas: S\u00e9rie Manuais do Hospital de Cl\u00ednicas da Unicamp; 2012. p. 16\u201323. https:\/\/intranet.hc.unicamp.br\/manuais\/cedmac.pdf. Accessed 05 September 2019."},{"key":"131_CR24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/jps.21530","volume":"98","author":"JF Carpenter","year":"2009","unstructured":"Carpenter JF, Randolph TW, Jiskoot W, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98:1201\u20135. https:\/\/doi.org\/10.1002\/jps.21530.","journal-title":"J Pharm Sci"},{"key":"131_CR25","doi-asserted-by":"publisher","first-page":"E501","DOI":"10.1208\/aapsj080359","volume":"8","author":"AS Rosenberg","year":"2006","unstructured":"Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8:E501\u20137.","journal-title":"AAPS J"},{"key":"131_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G. D\u2019 Haens G, Carbonez a, et al: influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348:601\u20138.","journal-title":"N Engl J Med"},{"key":"131_CR27","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1445\u201352.","journal-title":"Rheumatology (Oxford)"},{"key":"131_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711\u20135.","journal-title":"Arthritis Rheum"},{"key":"131_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","volume":"65","author":"A Vultaggio","year":"2010","unstructured":"Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Antiinfliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65:657\u201361. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02280.x Epub 2009 Nov 27.","journal-title":"Allergy"},{"key":"131_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/cea.12098","volume":"43","author":"A Matucci","year":"2013","unstructured":"Matucci A, Pratesi S, Petroni G, Nencini F, Virgili G, Milla M, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 2013;43:659\u201364. https:\/\/doi.org\/10.1111\/cea.12098.","journal-title":"Clin Exp Allergy"},{"key":"131_CR31","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","volume":"95","author":"RJ Farrell","year":"2000","unstructured":"Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn\u2019s disease. Am J Gastroenterol. 2000;95:3490\u20137.","journal-title":"Am J Gastroenterol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-00131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-020-00131-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-00131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:13:44Z","timestamp":1622070824000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-020-00131-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1186\/s42358-020-00131-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"9 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the ethical standards established in the Declaration of Helsinki of 1964 and its subsequent amendments and was approved by the Institution\u2019s local ethics committee (Comit\u00ea de \u00c9tica em Pesquisa em Seres Humanos do CHC\/UFPR # 66073817.0.0000.0096). All patients included in the study were fully informed about the research, and an ICF was obtained from all patients prior to their inclusion in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are aware of the full content of the manuscript and provided consent for the submission to Advances in Rheumatology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Valderilio Azevedo:Latin American Forum on Biosimilars Coordinator; Principal Investigator in clinical trials sponsored by AbbVie Farmac\u00eautica Ltda, Pfizer, Novartis Biociencias SA, Eli Lilly do Brasil Ltda., Boehringer Ingelheim do Brasil Qu\u00edmica e Farmac\u00eautica Ltda., GlaxoSmithKline do Brasil, Genentech, Inc. UCB Biopharma AS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}